Substance / Medication

Ocriplasmin

SNOMED 710290003 UMLS C0066522

Overview

Active Ingredient

ocriplasmin

RxNorm CUI

29998

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Retinal disorder

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion

NCT02322229Phase 4Completed62 enrolled

Assessment of Patients Treated With JETREA® for Vitreomacular Traction

NCT02035748Phase 4Completed628 enrolled

View all 2 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

The efficacy and safety of ocriplasmin for patients with vitreous macular traction.

Zhang Wen-Fei, Zhao Xin-Yu, Meng Li-Hui et al. · Acta Ophthalmol · 2022

PMID: 34021702Meta-Analysis

Effectiveness of ocriplasmin in real-world settings: A systematic literature review, meta-analysis, and comparison with randomized trials.

Khanani Arshad M, Constantine Ryan N, Blot Koenraad H et al. · Acta Ophthalmol · 2021

PMID: 33369248Meta-AnalysisFull text (PMC)

The effectiveness of ocriplasmin versus surgery for the treatment of macular holes: A systematic review and meta-analysis.

Yu Brian Edward, Sheidow Tom, Sambhi Raman-Deep Singh et al. · Eur J Ophthalmol · 2021

PMID: 32731755Meta-Analysis

Efficacy and Safety of Ocriplasmin Use for Vitreomacular Adhesion and Its Predictive Factors: A Systematic Review and Meta-Analysis.

Chen Xi, Li Min, You Ran et al. · Front Med (Lausanne) · 2021

PMID: 35096864Meta-AnalysisFull text (PMC)

Ocriplasmin for symptomatic vitreomacular adhesion.

Neffendorf James E, Kirthi Varo, Pringle Edward et al. · Cochrane Database Syst Rev · 2017

PMID: 29040800Meta-AnalysisFull text (PMC)

Review of economic studies and budget impact analysis of ocriplasmin as a treatment of vitreomacular traction.

García-Pérez L, Abreu-González R, Pérez-Ramos J et al. · Arch Soc Esp Oftalmol · 2016

PMID: 26920947Meta-Analysis

Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Chatziralli Irini, Theodossiadis George, Xanthopoulou Paraskevi et al. · Graefes Arch Clin Exp Ophthalmol · 2016

PMID: 27137631Meta-Analysis

Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA.

Yu Tiffany M, Dugel Pravin U, Haller Julia A et al. · J Comp Eff Res · 2018

PMID: 30350717RCT

Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction-Validation and refinement of a multivariable prediction model.

Paul Christoph, Müller Hans-Helge, Raber Thomas et al. · PLoS One · 2022

PMID: 35877658ObservationalFull text (PMC)

OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.

Steel David H W, Patton Niall, Stappler Theodor et al. · Retina · 2021

PMID: 32496343ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ocriplasmin (substance)
SNOMED CT: 710290003
UMLS CUI: C0066522
RxNorm CUI: 29998

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.